NEW YORK – Chinese infectious disease startup Vision Medicals has raised $14 million in a Series A financing round.
The round, which closed last week, was led by Volcanics Venture and CASH Capital.
The company, founded in May 2018 and headquartered in Guangzhou in southern China, has developed a CRISPR-based rapid diagnostics platform for pathogen detection and a metagenomics/metatranscriptomics platform.
It also has a proprietary pathogen nucleic acid enrichment technology (Patho-NET) and microbial databases.
Vision Medicals said it focuses on precision medicine for infectious diseases, including meningitis, encephalitis, respiratory infections, and bloodstream infections.